Vaccine Development Partners
Syntiron is part of the family-owned EW Group. The EW Group specializes in animal genetics, animal nutrition and animal health, operates in over 100 countries and records consistent international growth. Its positive outlook and global orientation have led to stable and steady expansion. EW Group’s family-owned structure fosters highly progressive strategies for the future that include long-term investments such as vaccine development.
Since 2006, Syntiron has been awarded six Small Business Innovation Research grants from the National Institute for Allergy and Infectious Disease (NIAID) for the research and development of vaccines against E. coli, Salmonella spp., Staphylococcus aureus and Yersinia pestis.
US Department of Defense/DTRA
In 2009, Syntiron received a $4.1 million contract from the US Defense Threat Reduction Agency (DTRA) for the development of vaccines to protect against three potential bacterial biowarfare agents – Bacillus anthracis (anthrax), Yersinia pestis (plague) and Burkholderia pseudomallei (melioidosis).
Latham Biopharm Group
Latham Biopharm Group unites teams and technology in the biotechnology arena to drive products toward commercialization. LBG has worked with Syntiron since 2018 on preclinical development, manufacturing, regulatory and clinical development.
Minnesota Medical Alley
Syntiron is proud to be a member of Medical Alley, a Minnesota-based trade organization with nearly 700 member organizations. Medical Alley affords Syntiron significant benefits such as educational seminars, networking opportunities, and advocacy in legislative and regulatory matters at local, state and federal levels.
Partner with us.
Be AN ALLOY ALLY.
Syntiron actively seeks partnerships that contribute to the advancement of human vaccines. For more information on our project and partnership opportunities, please contact us.
1000 Westgate Drive
St Paul MN 55114